Get the Stockscreener App
17.63
0.62%
-0.11
Upstream Bio Inc stock is traded at $17.63, with a volume of 289.08K.
It is down -0.62% in the last 24 hours and up +64.00% over the past month.
Upstream Bio Inc is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. It is developing verekitug, the known antagonist currently in clinical development that targets the receptor for Thymic Stromal Lymphopoietin (TSLP), a cytokine that is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune-mediated diseases.
See More
Previous Close:
$17.74
Open:
$17.83
24h Volume:
289.08K
Relative Volume:
0.63
Market Cap:
$950.42M
Revenue:
$2.22M
Net Income/Loss:
$-40.51M
P/E Ratio:
-13.72
EPS:
-1.2847
Net Cash Flow:
$-46.53M
1W Performance:
-6.87%
1M Performance:
+64.00%
6M Performance:
+120.93%
1Y Performance:
+0.00%
1-Day Range:
$17.54
$18.48
1-Week Range:
$16.02
$19.37
52-Week Range:
$5.14
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Name
Upstream Bio Inc
Sector
Industry
Phone
781-208-2466
Address
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
17.63 | 971.45M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Initiated | William Blair | Outperform |
Upstream Bio Inc Stock (UPB) Latest News
Can Upstream Bio Inc. Outperform Peers After Recent PullbackQuarterly Earnings Report & Community Consensus Picks - newsyoung.net
Can trapped investors hope for a rebound in Upstream Bio Inc.2025 Market Sentiment & Short-Term High Return Ideas - Newser
Analyzing Upstream Bio Inc. with risk reward ratio charts2025 Trading Recap & Consistent Growth Stock Picks - Newser
Chart based exit strategy for Upstream Bio Inc.Earnings Performance Report & Weekly Stock Performance Updates - Newser
Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug - MSN
Upstream Bio Inc. stock momentum explainedRate Hike & Daily Growth Stock Investment Tips - Newser
Upstream Bio Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingAnalyst Upgrade & Daily Oversold Stock Bounce Ideas - Newser
Analyzing recovery setups for Upstream Bio Inc. investorsJuly 2025 Retail & Daily Chart Pattern Signals - Newser
What to expect from Upstream Bio Inc. in the next 30 days2025 Momentum Check & Daily Price Action Insights - Newser
Short interest data insights for Upstream Bio Inc.2025 Technical Patterns & Real-Time Volume Analysis Alerts - Newser
Upstream Bio Inc. Charts Flash Early Recovery SignalsQuarterly Market Review & Consistent Profit Focused Trading Strategies - 선데이타임즈
Does Upstream Bio Inc. qualify in momentum factor screeningDividend Hike & AI Forecast for Swing Trade Picks - Newser
Watch for Trend Continuation in Upstream Bio Inc. Next WeekInflation Watch & Stepwise Swing Trade Plans - newsimpact.co.kr
How to use a screener to detect Upstream Bio Inc. breakoutsSwing Trade & Long-Term Safe Investment Ideas - Newser
Key resistance and support levels for Upstream Bio Inc.Entry Point & Expert Curated Trade Setup Alerts - Newser
Has Upstream Bio Inc. formed a bullish divergenceWeekly Trend Summary & High Return Trade Opportunity Guides - Newser
Analyzing net buyer seller activity in Upstream Bio Inc.Fed Meeting & Target Return Focused Stock Picks - Newser
Real time social sentiment graph for Upstream Bio Inc.Market Trend Report & Verified Stock Trade Ideas - Newser
Upstream Bio (UPB) Q2 R&D Soars 169% - AOL.com
Building trade automation scripts for Upstream Bio Inc.July 2025 Drop Watch & Free Expert Verified Stock Movement Alerts - Newser
XTX Topco Ltd Takes $78,000 Position in Upstream Bio, Inc. (NASDAQ:UPB) - Defense World
Real time breakdown of Upstream Bio Inc. stock performanceTreasury Yields & High Accuracy Trade Signal Alerts - Newser
Tools to assess Upstream Bio Inc.’s risk profileDollar Strength & Real-Time Volume Surge Alerts - Newser
Is it too late to sell Upstream Bio Inc.Trade Exit Summary & Safe Entry Zone Identification - Newser
Can Upstream Bio's (UPB) Rising Losses Outpace Revenue Growth in Its Long-Term Strategy? - simplywall.st
Ichimoku Cloud Indicates Uncertainty Around Upstream Bio Inc.July 2025 Volume & Reliable Entry Point Alerts - sundaytimes.kr
Upstream Bio Appoints Stacy Price as Chief Technology Officer - The Globe and Mail
Upstream Bio Inc. stock retracement – recovery analysisFree Reliable Chart-Based Trade Entries - Newser
Comparing Upstream Bio Inc. in custom built stock radarsFree Short Term Buy Zone Stock Alerts - Newser
What makes Upstream Bio Inc. stock price move sharplyForecasting Stock Moves with AI Insights - Newser
How Efficient Is Upstream Bio Inc. at Controlling Operating CostsChart Signal and Short-Term Forecast Tracker - Newser
Upstream Bio Inc Stock (UPB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Upstream Bio Inc Stock (UPB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):